Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BMYBristol-Myers SquibbRunning, no new patients

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Melanoma

3Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Sep 9, 2026 · was worth 5, fading over time

    +2.6
Worry score3

Score over time

Stage
Phase 3
Patients
579 (final count)
Started
Mar 6, 2023
Main results expected
Aug 4, 2025
Fully finished
Nov 18, 2027
Results posted
Aug 26, 2026

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale

    Measured over: Pre-dose (Day 1 to Day 28)

  • Adjusted Time-Averaged Relatlimab Serum Concentration Over the First 28 Days (Cavgd28-Rela) on Natural Logarithmic Scale

    Measured over: Pre-dose (Day 1 to Day 28)

  • Adjusted Trough Nivolumab Serum Concentration at Steady-State (Cminss-Nivo) on Natural Logarithmic Scale

    Measured over: Pre-dose (Day 1 to Day 28)

  • Adjusted Trough Relatlimab Serum Concentration at Steady-State (Cminss-Rela) on Natural Logarithmic Scale

    Measured over: Pre-dose (Day 1 to Day 28)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT05625399 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05625399) ↗